Effect of Sequential Therapy with Edaravone Dexborneol on Prognosis in Patients with Progressive Cerebral Infarction
Objective: To analyze the effects of sequential therapy with edaravone dexborneol on neurological function, inflammatory factors, and prognosis in patients with progressive cerebral infarction. Methods: Sixty patients with acute progressive cerebral infarction treated in our hospital from June 2025 to December 2025 were enrolled and divided into two groups by the random number table method, with 30 subjects in each group. The control group received conventional antiplatelet therapy, while the observation group received sequential therapy with edaravone dexborneol in addition to the control treatment. The intervention outcomes were compared between the two groups. Results: The total clinical effective rate and improvements in neurological function and inflammatory indicators in the observation group were better than those in the control group, and Hcy, NSE, and the incidence of adverse reactions were lower (P < 0.05). Conclusion: Sequential therapy with edaravone dexborneol can improve neurological function, reduce inflammation and neurological injury, and has good safety in patients with progressive cerebral infarction, warranting clinical promotion.
[1] Wang F, Kang J, Chen XF, et al., 2025, Efficacy of Edaravone Dexborneol Combined with Compound Troxerutin in Patients with Acute Progressive Cerebral Infarction. Chinese Journal of Drug Application and Monitoring, 22(3): 416–420.
[2] Li YC, Han GS, Dou ST, et al., 2023, Clinical Study of Edaravone Dexborneol Combined with Butylphthalide Injection in the Treatment of Patients with Acute Progressive Cerebral Infarction. The Chinese Journal of Clinical Pharmacology, 39(6): 763–767.
[3] Wang K, Rong MM, Yang JM, et al., 2025, Clinical Observation of Compound Brain Peptide Ganglioside Combined with Edaravone Dexborneol in the Treatment of Progressive Cerebral Infarction. Chinese Journal of Practical Nervous Diseases, 28(2): 202–206.
[4] Lei M, Geng JC, Zhu J, et al., 2024, Effect of Honglonggen Decoction Combined with Edaravone Dexborneol on the Risk of Progressive Cerebral Infarction in Patients with Cerebral Infarction after Thrombolysis. Acta Chinese Medicine, 39(12): 2678–2684.
[5] Xia XS, Chen K, Yu W, et al., 2025, Effect of Butylphthalide Combined with Edaravone Dexborneol on Patients with Acute Progressive Cerebral Infarction. Sichuan Journal of Physiological Sciences, 47(5): 1054–1056.
[6] Wan YD, 2023, Clinical Effect of Edaravone Dexborneol in the Treatment of Acute Progressive Large-Artery Atherosclerotic Cerebral Infarction. Chinese and Foreign Medical Research, 21(35): 26–29.
